Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.